{
    "clinical_study": {
        "@rank": "151531", 
        "acronym": "VAY736Y", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1- relapsed/refractory CLL patients", 
                "arm_group_type": "Experimental", 
                "description": "Patients with relapsed/refractory CLL with two or three prior treatment regimens"
            }, 
            {
                "arm_group_label": "Arm 2 - rituximab or ofatumumab refractory CLL patients", 
                "arm_group_type": "Experimental", 
                "description": "Patients with relapsed/refractory CLL with four or more prior treatment regimens"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and preliminary efficacy of escalating doses of VAY736 in\n      relapsed or refractory CLL patients."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This Phase 1, multicenter, open-label, study will investigate the safety, pharmacokinetics,\n      pharmacodynamics, and preliminary antil-CLL activity of VAY736 in patients with\n      relapsed/refractory CLL who have received at least two prior regimens.  The study will\n      include one arm in the dose escalation phase and two arms in the dose expansion phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Dose escalation: Relapsed/refractory CLL following at least -two prior treatment\n             regimen\n\n          -  Dose expansion:\n\n               -  Arm 1: Relapsed/refractory CLL following two to three prior treatment regimens\n\n               -  Arm 2: Relapsed/refractory CLL following four or more prior treatment regimens\n\n          -  Discontinued any previous anti-cancer and investigational therapy including\n             radiation, radioimmunotherapy, and monoclonal antibody therapy for at least 28 days\n             or 5 half-lives of the investigational product, whichever is longer, before study\n             treatment administration, and must have recovered fully from the adverse effects of\n             such treatment before beginning study treatment\n\n          -  Discontinued prior alemtuzumab therapy for at least 6 months\n\n          -  Age 18 years\n\n          -  Eastern cooperative oncology group (ECOG) performance status grade \u2264 1\n\n          -  Life expectancy > 3 months\n\n          -  Meet the following laboratory criteria (must be obtained within 14 days of\n             enrollment):\n\n             \u2022 Adequate end-organ function as assessed by laboratory tests, as specified in the\n             protocol.\n\n          -  Written informed consent obtained prior to any screening procedures\n\n        Exclusion Criteria:\n\n          -  Major surgery within 28 days before study treatment or have not recovered fully from\n             the adverse effects of any major or minor surgical procedures before study treatment\n\n          -  History of another primary malignancy that is currently clinically significant or\n             currently requires active intervention (except adequately treated in situ carcinoma\n             of the cervix or non-melanoma carcinoma of the skin or any other curatively treated\n             malignancy that has not been treated in the prior 3 months or expected to require\n             treatment for recurrence during the course of the study).\n\n          -  Prior anaphylactic or other severe infusion reaction such that the patient is unable\n             to tolerate human immunoglobulin or monoclonal antibody administration\n\n          -  Clinically significant central nervous system disease\n\n          -  Myocardial infarction within 6 months prior to enrollment or New York Hospital\n             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe\n             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute\n             ischemia or significant conduction system abnormalities in the opinion of the\n             investigator\n\n          -  History of an active infection requiring systemic therapy within 14 days before study\n             treatment. Prophylactic antibiotics and antiviral therapies are permitted.\n\n          -  Active autoimmune disease requiring immunosuppressive therapy\n\n          -  Known history of human immunodeficiency virus (HIV) or active infection with\n             hepatitis C virus or hepatitis B virus or any active bacterial, viral, or fungal\n             infection requiring systemic therapy\n\n          -  Ongoing corticosteroid use (>10 mg/day prednisone or equivalent)\n\n          -  Pregnant or nursing (lactating) women.\n\n          -  Sexually active males must use a condom during intercourse while taking the drug and\n             for 3 months after stopping treatment and should not father a child in this period. A\n             condom is required to be used also by vasectomized men in order to prevent delivery\n             of the drug via seminal fluid."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137889", 
            "org_study_id": "CVAY736Y2101", 
            "secondary_id": "2011-005485-38"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1- relapsed/refractory CLL patients", 
                "Arm 2 - rituximab or ofatumumab refractory CLL patients"
            ], 
            "description": "VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.", 
            "intervention_name": "VAY736", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "CLL", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer SC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Belgium", 
                "France", 
                "Germany", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Muticenter, Open-label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 When Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: National Health and Medical Research Council", 
                "Germany: Ministry of Health", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "France: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Frequency and characteristics of DLTs. Determination of the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of VAY736 when administered weekly in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) (dose escalation only).", 
            "measure": "Dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the preliminary anti-CLL (chronic lymphocytic leukemia) activity of VAY736 at the MTD/RDE in patients with relapsed or refractory CLL.", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Plasma concentrations to characterize the pharmaconinetics of VAY736", 
                "measure": "VAY736 plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To assess the immunogenicity of VAY736.", 
                "measure": "Blood Serum concentrations of antibodies to VAY736", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To assess the pharmacodynamics of VAY736.", 
                "measure": "Hematology parameters of VAY736", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To assess the safety and tolerability of VAY736 by type, frequency, and severity of AEs, changes in hematology and blood chemistry values, assessments of physical examinations, vital signs, and electrocardiograms.", 
                "measure": "Number of patients with Advers Events (AEs) as a measure of safety and tolerability.", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "PK parameters include AUC0-tlast, Cmax, T1/2", 
                "measure": "PharmacoKinetics (PK) parameters of VAY736", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To assess the pharmacodynamic effect of VAY736.", 
                "measure": "Receptor occupancy for VAY736", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Study terminated on 04Oct2013 for business reasons after being on hold for 10 months.  Early\n    termination was not due to safety concerns."
    }
}